Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.45 |
| ▸ | LPL | P06858 | 4/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401337 | 1.00 | LIPG (0.45) | LIPGLPLTDO2AKR1C3AKR1C2 | |
| SCHEMBL2648752 | 0.85 | LPL (0.47) | LIPGLPLTDO2ROCK1PDGFRB | |
| SCHEMBL28470742 | 0.84 | LIPG (0.60) | LIPGLPLTDO2ROCK1PDGFRB | |
| SCHEMBL6218782 | 0.84 | LPL (0.48) | LIPGLPLTDO2ROCK1PDGFRB | |
| SCHEMBL20615766 | 0.83 | LPL (0.43) | LIPGLPLTDO2ROCK1PDGFRB | |
| SCHEMBL2651616 | 0.82 | LPL (0.42) | LIPGLPLTDO2ROCK1PDGFRB | |
| SCHEMBL22636737 | 0.81 | LIPG (0.45) | LIPGLPLTDO2PDGFRBKDR | |
| SCHEMBL29430844 | 0.81 | LIPG (0.45) | LIPGLPLTDO2PDGFRBKDR | |
| SCHEMBL20905062 | 0.81 | LIPG (0.50) | LIPGLPLTDO2ROCK1PDGFRB | |
| SCHEMBL31642814 | 0.80 | LIPG (0.48) | LIPGLPLPDGFRBKDRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1409488-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-6960598-B2 | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. | 2005-11-01 | — | — | US | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1409488-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-04-21 | — | — | EP | disclosed |
| US-6696444-B2 | NEUROTRANSMITTER ANTAGONISTS COMPRISING COMPOUNDS SUCH AS 4,2'-DIFLUORO-5'-(3-(1-FLUORO-1-METHYLETHYL)IMIDAZO(1,2-B)(1,2 ,4) TRIAZIN-7-YL)BIPHENYL-2-CARBONITRILE, ADMINISTERED FOR THE PROPHYLAXIS OF HEADACHES OR AS ANTICONVULSANTS | MERCK SHARPE & DOHME (GB) | 2004-02-24 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1343788-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6617326-B2 | For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety and convulsions | MERCK SHARP & DOHME LTD. | 2003-09-09 | — | — | US | disclosed |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-20 | — | — | US | disclosed |
| WO-2003008418-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003006464-A1 | (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074772-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | LIPG 4868/4885LPL 4750/4885TDO2 1037/4885 |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | GABRA2, GABRA3, GABRA1 | LIPG 4868/4885LPL 4826/4885TDO2 1343/4885 |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | LIPG 4869/4885LPL 4840/4885TDO2 578/4885 |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | GABRA1, GABRA4, GABRA6 | LIPG 4342/4885LPL 3649/4885TDO2 3647/4885 |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | GABRA2, GABRA1, GABRA3 | LIPG 4874/4885LPL 4828/4885TDO2 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.